How is Arymo ER formulated to be abuse deterrent?
Medically reviewed by Judith Stewart, BPharm. Last updated on Feb 23, 2021.
Arymo ER (morphine sulfate) tablets are formulated with Egalet's proprietary Guardian™ Technology to a create a physical and chemical barrier to prevent abuse.
Arymo ER has been discontinued and is no longer available for use.
What is Arymo ER?
Arymo ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Arymo ER is formulated as extended-release tablets. It is a Schedule II controlled substance with a high potential for abuse and and dependence.
How is Arymo ER Abuse-Deterrent?
Arymo ER tablets are designed to be difficult to manipulate for the purpose of misuse and abuse.
The Guardian™ Technology is a polymer matrix tablet technology that utilizes a novel application of the manufacturing process of injection molding, which results in tablets that are physically hard and difficult to manipulate. Arymo ER tablets have increased resistance to cutting, crushing, grinding or breaking compared to non-abuse-deterrent morphine sulfate extended-release tablets.
The tablets are also resistant to chemical manipulation making abuse via injection difficult, as contact with liquid results in a viscous hydrogel that is difficult to transfer into a syringe.
Related Medical Questions
- Is Vyvanse a controlled substance / narcotic drug?
- Is Latuda a controlled substance?
- How long do drugs stay in your system?
- Is Belbuca a controlled substance?
- Is Wakix a controlled substance?
- Arymo ER Information for Consumers
- Arymo ER Information for Healthcare Professionals (includes dosage details)
- Side Effects of Arymo ER (detailed)